In short
Juniperus communis, summitates, ethanol. infusum Ø is a herbal substance prepared from the tips of juniper branches. It is being studied in irritable bowel syndrome (IBS). One authorised Phase 3 trial is testing an oral dilution of this substance against placebo in 106 people with IBS, measuring how much gastrointestinal discomfort changes over eight weeks of treatment.
Juniperus communis, summitates, ethanol. infusum Ø is a herbal preparation made from the fresh tips of common juniper branches, extracted with ethanol. It is an investigational substance being studied in irritable bowel syndrome (IBS). One authorised Phase 3 trial is testing an oral dilution of this preparation against placebo in 106 people with IBS.
Key points
- Phase 3 trial in irritable bowel syndrome tests juniper tips as an oral dilution against placebo.
- The trial is authorised but not yet recruiting, with a planned enrolment of 106 participants.
- The main measure is the change in gastrointestinal discomfort on a 0–100 mm visual analogue scale over eight weeks.
- Treatment is an oral dilution of Juniperus communis, summitates, ethanol. infusum Ø.
- The trial compares the juniper preparation with a placebo to see whether it reduces IBS discomfort.
- The registry record is 2026-526668-19-00 in the EU Clinical Trials Information System.
What is Juniperus communis, summitates, ethanol. infusum Ø?
Juniperus communis, summitates, ethanol. infusum Ø is a herbal substance prepared from the summitates, or branch tips, of the common juniper tree (Juniperus communis). The name describes the preparation: the plant part used, the ethanol extraction, and the Ø symbol indicating an undiluted mother tincture. The trial record lists the intervention as Amara-Tropfen Dilution, an oral preparation containing 1046 microlitres of the substance. No marketing authorisation is reported in these records, so it is considered an investigational substance for the studied indication.
How does Juniperus communis, summitates, ethanol. infusum Ø work?
The registry data do not describe a molecular target or mechanism of action for this preparation. The trial record does not provide information on how the juniper preparation might affect irritable bowel syndrome. The study is designed to measure whether the substance reduces gastrointestinal discomfort, but the biological mechanism is not stated in the available data.
Which conditions is it used or studied for?
- Irritable bowel syndrome (IBS) — a common digestive disorder that causes abdominal discomfort, bloating, and changes in bowel habits. The authorised Phase 3 trial is studying whether the juniper preparation reduces gastrointestinal discomfort in people with IBS.
How is Juniperus communis, summitates, ethanol. infusum Ø given?
The trial record describes the intervention as an oral dilution. The preparation is Amara-Tropfen Dilution, given by mouth at a volume of 1046 microlitres per dose. The pharmaceutical form is a dilution for oral use. No other formulations are reported in the available data.
What do the clinical trials show?
There is one clinical trial of Juniperus communis, summitates, ethanol. infusum Ø in the registry. It is a Phase 3 interventional study in irritable bowel syndrome, authorised but not yet recruiting. The trial plans to enrol 106 participants.
The trial compares the juniper preparation with placebo. Participants receive either the oral dilution or a placebo, and the study measures how gastrointestinal discomfort changes over eight weeks of treatment.
What is the trial measuring?
The primary outcome is the change in the intensity of gastrointestinal discomfort, measured on a visual analogue scale (VAS) from 0 to 100 mm, where 0 means no discomfort and 100 means the most intense discomfort. The trial compares the weekly mean VAS value during eight weeks of treatment with the baseline value, which is the mean of at least four VAS values documented during the seven days before randomisation.
Who can take part in the trial?
The trial is for patients with irritable bowel syndrome. The registry record does not provide detailed eligibility criteria such as age range, IBS subtype, or exclusion conditions. The planned enrolment is 106 participants, and the study is interventional, meaning participants receive either the juniper preparation or placebo.
What is the status of the trial?
The trial is authorised in the EU Clinical Trials Information System. The status means the trial has received regulatory approval to proceed but has not yet started recruiting participants. The registry identifier is 2026-526668-19-00.
What side effects are known?
The available registry data do not report side effects for Juniperus communis, summitates, ethanol. infusum Ø. No supplementary sources with safety information were provided, so no side effect profile can be described here.